444 related articles for article (PubMed ID: 23045324)
1. Hormone response in ovarian cancer: time to reconsider as a clinical target?
Modugno F; Laskey R; Smith AL; Andersen CL; Haluska P; Oesterreich S
Endocr Relat Cancer; 2012 Dec; 19(6):R255-79. PubMed ID: 23045324
[TBL] [Abstract][Full Text] [Related]
2. Gonadotropin signalling in epithelial ovarian cancer.
Mertens-Walker I; Baxter RC; Marsh DJ
Cancer Lett; 2012 Nov; 324(2):152-9. PubMed ID: 22634496
[TBL] [Abstract][Full Text] [Related]
3. [Rationale for the approach to the choice of hormone therapy for ovarian cancer].
Lisianskaia AS
Vopr Onkol; 2014; 60(3):274-9. PubMed ID: 25033677
[TBL] [Abstract][Full Text] [Related]
4. Endocrine therapy in ovarian cancer: where do we stand?
Paleari L; DeCensi A
Curr Opin Obstet Gynecol; 2018 Feb; 30(1):17-22. PubMed ID: 29176513
[TBL] [Abstract][Full Text] [Related]
5. Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer.
Bonaventura A; OʼConnell RL; Mapagu C; Beale PJ; McNally OM; Mileshkin LR; Grant PT; Hadley AM; Goh JCH; Sjoquist KM; Martyn J; DeFazio A; Scurry J; Friedlander ML;
Int J Gynecol Cancer; 2017 Jun; 27(5):900-906. PubMed ID: 28498256
[TBL] [Abstract][Full Text] [Related]
6. Revisiting the role of antiandrogen strategies in ovarian cancer.
Papadatos-Pastos D; Dedes KJ; de Bono JS; Kaye SB
Oncologist; 2011; 16(10):1413-21. PubMed ID: 21948654
[TBL] [Abstract][Full Text] [Related]
7. Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.
Wuntakal R; Seshadri S; Montes A; Lane G
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD011322. PubMed ID: 27356090
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoids inhibit cell death in ovarian cancer and up-regulate caspase inhibitor cIAP2.
Runnebaum IB; Brüning A
Clin Cancer Res; 2005 Sep; 11(17):6325-32. PubMed ID: 16144937
[TBL] [Abstract][Full Text] [Related]
9. Endocrine therapy in epithelial ovarian cancer.
Langdon SP; Gourley C; Gabra H; Stanley B
Expert Rev Anticancer Ther; 2017 Feb; 17(2):109-117. PubMed ID: 27967255
[TBL] [Abstract][Full Text] [Related]
10. Targeting pathways contributing to epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer.
Huang RY; Chung VY; Thiery JP
Curr Drug Targets; 2012 Dec; 13(13):1649-53. PubMed ID: 23061545
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer.
Elattar A; Warburton KG; Mukhopadhyay A; Freer RM; Shaheen F; Cross P; Plummer ER; Robson CN; Edmondson RJ
Gynecol Oncol; 2012 Jan; 124(1):142-7. PubMed ID: 22001143
[TBL] [Abstract][Full Text] [Related]
12. Green tea for ovarian cancer prevention and treatment: a systematic review of the in vitro, in vivo and epidemiological studies.
Trudel D; Labbé DP; Bairati I; Fradet V; Bazinet L; Têtu B
Gynecol Oncol; 2012 Sep; 126(3):491-8. PubMed ID: 22564714
[TBL] [Abstract][Full Text] [Related]
13. Hormone therapy for epithelial ovarian cancer.
Langdon SP; Smyth JF
Curr Opin Oncol; 2008 Sep; 20(5):548-53. PubMed ID: 19106659
[TBL] [Abstract][Full Text] [Related]
14. Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer.
van der Bilt AR; de Vries EG; de Jong S; Timmer-Bosscha H; van der Zee AG; Reyners AK
Crit Rev Oncol Hematol; 2012 Nov; 84(2):224-42. PubMed ID: 22525643
[TBL] [Abstract][Full Text] [Related]
15. EGFR/HER-targeted therapeutics in ovarian cancer.
Wilken JA; Badri T; Cross S; Raji R; Santin AD; Schwartz P; Branscum AJ; Baron AT; Sakhitab AI; Maihle NJ
Future Med Chem; 2012 Mar; 4(4):447-69. PubMed ID: 22416774
[TBL] [Abstract][Full Text] [Related]
16. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
[TBL] [Abstract][Full Text] [Related]
17. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.
Gui T; Shen K
Cancer Epidemiol; 2012 Oct; 36(5):490-6. PubMed ID: 22818908
[TBL] [Abstract][Full Text] [Related]
18. Hormonal therapy in ovarian cancer.
Zheng H; Kavanagh JJ; Hu W; Liao Q; Fu S
Int J Gynecol Cancer; 2007; 17(2):325-38. PubMed ID: 17362310
[TBL] [Abstract][Full Text] [Related]
19. PARP Inhibitors in Epithelial Ovarian Cancer.
Taylor KN; Eskander RN
Recent Pat Anticancer Drug Discov; 2018; 13(2):145-158. PubMed ID: 29205122
[TBL] [Abstract][Full Text] [Related]
20. Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis.
Paleari L; Gandini S; Provinciali N; Puntoni M; Colombo N; DeCensi A
Gynecol Oncol; 2017 Sep; 146(3):504-513. PubMed ID: 28705409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
